USP and Ph. Eur. harmonization is one of the most underused levers in multi-market QC laboratories: it lets you run a test once and claim compliance against several pharmacopoeias, cutting duplication, costs and method transfer risks. It is also where the most expensive mistake is made: assuming that "harmonized" means "identical". Between 2025 and 2026 the landscape changed substantially — new revisions signed off by the PDG, a rewritten working procedure, new pharmacopoeias joining and the first prospective harmonization project on an active substance — so it is worth taking fresh stock of what is actually aligned and what is not.
USP and Ph. Eur. harmonization: what "harmonized" really means
A "harmonized" general chapter or monograph is a text elaborated and signed off jointly by the participating pharmacopoeias, which each of them then implements under its own editorial procedures. This has three operational consequences that make a difference in audits:
- the texts are equivalent in outcome, but not necessarily identical word for word;
- there may be non-harmonised parts and local differences (reagents, expression of results, procedural details) that must be identified and managed;
- the applicable edition and supplement remain those of the destination pharmacopoeia: harmonization is no exemption from compendial watch or change control.
Telling an inspector "the chapter is harmonized" without showing how that choice is documented in the in-house method, SOPs and training amounts to saying "trust us". Harmonization is an advantage only when translated into QMS evidence.
Who drives the work: the PDG and the 2025-2026 updates
The engine of harmonization is the Pharmacopoeial Discussion Group (PDG), the informal body founded in 1989 by the European Pharmacopoeia (EDQM), the Japanese Pharmacopoeia (JP) and USP, with the WHO as observer. Since 2023 the group is no longer "trilateral": the Indian Pharmacopoeia Commission (IPC), after a pilot started in October 2022, has been a full member since October 2023 and will host the 2026 annual meeting in Ghaziabad.
The most relevant recent news for QC professionals:
- at the Tokyo annual meeting (30 September - 1 October 2025) the PDG confirmed the sign-off of two major revisions: general chapter Q-09 Particulate Contamination (major revision) and chapter Q-02 Disintegration, which introduces Test B for dosage forms larger than 18 mm;
- the Korean Pharmacopoeia attended as a candidate: under the new membership framework it will observe PDG activities for one year, followed by an active participation phase of at least one year;
- the PDG working procedure was revised (October 2025): "non-harmonised attributes" are merged into "non-harmonised parts" and the white diamond symbols historically used to flag them disappear — a notation change laboratories will need to absorb when reading the chapters;
- in July 2026 Ph. Eur., JP and USP announced the first trilateral prospective harmonization project on osimertinib mesilate (API) and the corresponding tablets: for the first time harmonization moves beyond the historical scope of general chapters and excipients towards single monographs for an active substance and a finished product, written jointly from the start.
To date more than twenty general chapters are harmonized — including bacterial endotoxins (Ph. Eur. 2.6.14), sterility (2.6.1) and disintegration (2.9.1) — plus numerous excipient monographs; further revisions, such as dissolution, are ongoing.
The harmonization landscape changes several times a year, between PDG sign-offs and local implementation in supplements: with The Pragmatic GMP, our free weekly newsletter, you get the regulatory updates that impact your laboratory, already translated into concrete actions.
ICH Q4B and interchangeability: what you can rationalize
For some chapters, the PDG's textual harmonization is complemented by the ICH Q4B framework: the Q4B annexes declare the regulatory interchangeability of specific harmonized chapters, i.e. the possibility of applying the text of one pharmacopoeia and being accepted in the other ICH regions as well. This underpins the "test once, comply many" logic: one method, one SOP, one instrument qualification, a single LIMS workflow.
There are developments here too: the PDG has launched a proof-of-concept for the maintenance of three Q4B annexes — Annex 6 (Uniformity of Dosage Units), Annex 7 (Dissolution) and Annex 8 (Sterility) — involving the pharmacopoeias of ICH regulatory members that do not sit in the PDG. The goal is to keep aligned over time texts that today risk diverging at every local revision.
Allowed differences and non-harmonised parts: the operational trap
The "allowed" differences between harmonized versions should not change the compliance decision, but they can change laboratory practice: reagent preparation, units of measurement, procedural details, reporting conventions. The table summarizes where harmonization really helps and where it must not be taken for granted.
| Area | Where harmonization helps | What remains at risk |
|---|---|---|
| General chapters (methods) | Single SOP, single training, less duplication | Non-harmonised parts, differing local editions, new PDG notation to absorb |
| Excipient monographs | More consistent specifications across markets | Non-harmonized excipients or regional grades |
| API / finished product monographs | Limited benefit today; the osimertinib project opens the prospective path | Often significant divergences: never assume equivalence |
| Audit readiness | Stronger answers ("single harmonized method") | Without QMS evidence, harmonization defends nothing |
From paper to QMS: implementing without audit exposure
The process we recommend governing, whatever the size of the laboratory:
- Structured compendial watch: monitoring of PDG sign-offs, Ph. Eur. supplements, USP-NF and JP revisions, with assigned responsibilities.
- Joint QA/QC/RA impact assessment at every revision: effect on methods, system suitability, specifications, regulatory dossiers.
- Compendial equivalence statement in the in-house method: which pharmacopoeia is the source, which differences exist, which choice was made and why.
- Documented change control and retraining at every implementation, with evidence of QA review.
The weak point that surfaces most often in inspections is not the lack of harmonization but "on-paper" simplification: the single method exists, but it is not updated to the latest supplement, or the allowed differences live only in the analyst's memory.
GuideGxP recommendation
Treat every harmonized text as a three-level requirement: the text signed off by the PDG, its implementation in the destination pharmacopoeia, and your internal implementation. Only the third level is under your control, and it is the one the inspector verifies. Build a method-pharmacopoeia-market traceability matrix and review it at every supplement: a few hours per quarter that eliminate the most frequent finding category on this topic.
For a complete methodology — harmonization status, management of USP/Ph. Eur./JP/BP divergences, alternative methods and reference standards, with ready-to-use Excel and Word toolkits — see our guide Pharmacopoeias in GMP – Operational Guide to USP, Ph. Eur., JP and BP.
